Long-term durability and dose escalation patterns in infliximab therapy for psoriasis

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld et al. · The Lancet · 1999 · 2.4K citations

Medicine, Pharmacology, Pharmacotherapy +17

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Filip Baert, Maja Noman, Séverine Vermeire et al. · New England Journal of Medicine · 2003 · 2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

Kristian Reich, Frank O. Nestlé, Kim Papp et al. · The Lancet · 2005 · 1K citations

Medicine, Dermatology, Pharmacotherapy +12

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Umesh Chaudhari, Pat Romano, LD Mulcahy et al. · The Lancet · 2001 · 904 citations

Medicine, Pharmacology, Pharmacotherapy +11

Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial

Alice B. Gottlieb, Robert J. Evans, Shu Li et al. · Journal of the American Academy of Dermatology · 2004 · 581 citations

Medicine, Dermatology, Pharmacotherapy +12